Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Vinay Prasad, Christopher McCabe, Sham Mailankody

Research output: Contribution to journalArticle

Abstract

In hindsight, we realize that we could have been more precise when using the terms ‘profit’ and ‘revenue’ in our article ‘Low-value approvals and high prices might incentivize ineffective drug development’. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Pharmaceutical Preparations
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Addendum : Low-value approvals and high prices might incentivize ineffective drug development. / Prasad, Vinay; McCabe, Christopher; Mailankody, Sham.

In: Nature Reviews Clinical Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{7c953c4f094f4ebaaad240024235e29e,
title = "Addendum: Low-value approvals and high prices might incentivize ineffective drug development",
abstract = "In hindsight, we realize that we could have been more precise when using the terms ‘profit’ and ‘revenue’ in our article ‘Low-value approvals and high prices might incentivize ineffective drug development’. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.",
author = "Vinay Prasad and Christopher McCabe and Sham Mailankody",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41571-018-0120-1",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Addendum

T2 - Low-value approvals and high prices might incentivize ineffective drug development

AU - Prasad, Vinay

AU - McCabe, Christopher

AU - Mailankody, Sham

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In hindsight, we realize that we could have been more precise when using the terms ‘profit’ and ‘revenue’ in our article ‘Low-value approvals and high prices might incentivize ineffective drug development’. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.

AB - In hindsight, we realize that we could have been more precise when using the terms ‘profit’ and ‘revenue’ in our article ‘Low-value approvals and high prices might incentivize ineffective drug development’. Total revenue is defined as the receipts from sales1. Profit is defined as the excess of the receipts from sales over the spending of a business during any period1. Hence, profit is the total revenue minus the costs of a business, over a given period. Profit calculations include credit transactions and asset revaluations as well as cash transactions and changes in the value of real assets1.

UR - http://www.scopus.com/inward/record.url?scp=85056607571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056607571&partnerID=8YFLogxK

U2 - 10.1038/s41571-018-0120-1

DO - 10.1038/s41571-018-0120-1

M3 - Article

C2 - 30420734

AN - SCOPUS:85056607571

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -